DrugDashboards

Pantoprazole Sodium

Pantoprazole Sodium · PANTOPRAZOLE SODIUM 40 mg/10mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Sun Pharmaceutical Industries, Inc.

NDC 62756-0129-45 · 25 CARTON in 1 PACKAGE / 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. One of its named manufacturing plants, Sun Pharmaceutical Industries Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Historically, drugs in this position went on to a new shortage within 90 days about 0.7% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.7%chance of a new FDA shortage posting for pantoprazole sodium (injectable) in the next 90 days

sterile injectable · price up 28% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $12.94 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA077674
TE code
Approval date
Aug 19, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · TerminatedFeb 5, 2021
    SUN PHARMACEUTICAL INDUSTRIES INCFailed Impurity/Degradation Specifications

Manufacturers of Pantoprazole Sodium (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 3, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Civica, Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries LimitedPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Pantoprazole Sodium — NDC 62756-0129-45," retrieved September 3, 2026, https://drugdashboards.com/drug/62756012945.

Free to cite with attribution — see how the data is put together.